Top

Published in:

Open Access 01-12-2022 | Migraine | Review article

Brain barriers and their potential role in migraine pathophysiology

Authors: Astrid Wiggers, Håkan Ashina, Nouchine Hadjikhani, Abhay Sagare, Berislav V. Zlokovic, Martin Lauritzen, Messoud Ashina

Published in: The Journal of Headache and Pain | Issue 1/2022

Abstract

Migraine is a ubiquitous neurologic disease that afflicts people of all ages. Its molecular pathogenesis involves peptides that promote intracranial vasodilation and modulate nociceptive transmission upon release from sensory afferents of cells in the trigeminal ganglion and parasympathetic efferents of cells in the sphenopalatine ganglion. Experimental data have confirmed that intravenous infusion of these vasoactive peptides induce migraine attacks in people with migraine, but it remains a point of scientific contention whether their site of action lies outside or within the central nervous system. In this context, it has been hypothesized that transient dysfunction of brain barriers before or during migraine attacks might facilitate the passage of migraine-inducing peptides into the central nervous system. Here, we review evidence suggestive of brain barrier dysfunction in migraine pathogenesis and conclude with lessons learned in order to provide directions for future research efforts.

Ashina M, Ropper AH (2020) Migraine. N Engl J Med 383(19):1866–1876. https://doi.org/10.1056/NEJMra1915327CrossRefPubMed

Moskowitz MA (1984) The neurobiology of vascular head pain. Ann Neurol 16(2):157–168. https://doi.org/10.1002/ana.410160202CrossRefPubMed

Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA (2019) Migraine and the trigeminovascular system—40 years and counting. Lancet Neurol 18(8):795–804. https://doi.org/10.1016/s1474-4422(19)30185-1CrossRefPubMedPubMedCentral

Ashina M, Hansen JM, BO AD, Olesen J. (2017) Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol 13(12):713–724. https://doi.org/10.1038/nrneurol.2017.137CrossRefPubMed

Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15(4):275–292. https://doi.org/10.1038/nrd.2015.21CrossRefPubMed

Saunders NR, Dziegielewska KM, Møllgård K, Habgood MD (2018) Physiology and molecular biology of barrier mechanisms in the fetal and neonatal brain. J Physiol 596(23):5723–5756. https://doi.org/10.1113/JP275376CrossRefPubMedPubMedCentral

Kutuzov N, Flyvbjerg H, Lauritzen M (2018) Contributions of the glycocalyx, endothelium, and extravascular compartment to the blood–brain barrier. Proc Natl Acad Sci U S A 115(40):E9429–E9438. https://doi.org/10.1073/pnas.1802155115CrossRefPubMedPubMedCentral

Ermisch A, Brust P, Kretzschmar R, Rühle HJ (1993) Peptides and blood-brain barrier transport. Physiol Rev 73(3):489–527. https://doi.org/10.1152/physrev.1993.73.3.489CrossRefPubMed

Harper AM, MacKenzie ET, McCulloch J, Pickard JD (1977) Migraine and the blood-brain barrier. Lancet. 1(8020):1034–1036. https://doi.org/10.1016/s0140-6736(77)91262-4CrossRefPubMed

10.

Amin FM, Hougaard A, Cramer SP, Christensen CE, Wolfram F, Larsson HBW, Ashina M (2017) Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. Eur J Neurol 24(9):1116–1124. https://doi.org/10.1111/ene.13341CrossRefPubMed

11.

Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP, Larsson HBW, Ashina M (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 140(6):1633–1642. https://doi.org/10.1093/brain/awx089CrossRefPubMed

12.

Kim YS, Kim M, Choi SH, You SH, Yoo RE, Kang KM, Yun TJ, Lee ST, Moon J, Shin YW (2019) Altered vascular permeability in migraine-associated brain regions: evaluation with dynamic contrastenhanced MRI. Radiology. 292(3):713–720. https://doi.org/10.1148/radiol.2019182566CrossRefPubMed

13.

Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T, VanBrocklin HF, Goadsby PJ (2016) Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 139(Pt 7):1994–2001. https://doi.org/10.1093/brain/aww096CrossRefPubMedPubMedCentral

14.

Leira R, Sobrino T, Rodríguez-Yáñez M, Blanco M, Arias S, Castillo J (2007) MMP-9 immunoreactivity in acute migraine. Headache. 47(5):698–702. https://doi.org/10.1111/j.1526-4610.2006.00641.xCrossRefPubMed

15.

Imamura K, Takeshima T, Fusayasu E, Nakashima K (2008) Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache. 48(1):135–139. https://doi.org/10.1111/j.1526-4610.2007.00958.xCrossRefPubMed

16.

Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1(1):73–80. https://doi.org/10.1111/j.1468-1331.1994.tb00053.xCrossRefPubMed

17.

Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi A, Miller K, Gearing A (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893(1–2):104–112. https://doi.org/10.1016/S0006-8993(00)03294-7CrossRefPubMed

18.

Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, Wang X, Rosenberg GA, Lo EH, Moskowitz MA (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113(10):1447–1455. https://doi.org/10.1172/jci21227CrossRefPubMedPubMedCentral

19.

Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Gonçalves FM, Gerlach RF, Tanus-Santos JE (2009) Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta 408(1–2):60–64. https://doi.org/10.1016/j.cca.2009.07.008CrossRefPubMed

20.

Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J (2010) Matrix metalloproteinases during and outside of migraine attacks without aura. Cephalalgia. 30(3):303–310. https://doi.org/10.1111/j.1468-2982.2009.01954.xCrossRefPubMed

21.

Penkowa M, Florit S, Giralt M, Quintana A, Molinero A, Carrasco J, Hidalgo J (2005) Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J Neurosci Res 79(4):522–534. https://doi.org/10.1002/jnr.20387CrossRefPubMed

22.

Li M, Yang G, Xie B, Babu K, Huang C (2014) Changes in matrix metalloproteinase-9 levels during progression of atrial fibrillation. J Int Med Res 42(1):224–230. https://doi.org/10.1177/0300060513488514CrossRefPubMed

23.

Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, Arbeit LA (1996) Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 78(2):161–171. https://doi.org/10.1006/clin.1996.0025CrossRefPubMed

24.

Lauritzen M (1994) Pathophysiology of the migraine aura: the spreading depression theory. Brain. 117(1):199–210. https://doi.org/10.1093/brain/117.1.199CrossRefPubMed

25.

Karatas H, Erdener SE, Gursoy-Ozdemir Y et al (2013) Spreading depression triggers headache by activating neuronal Panx1 channels. Science 339(6123):1092–1095. https://doi.org/10.1126/science.1231897CrossRefPubMed

26.

Zhang XC, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R (2010) Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci 30(26):8807–8814. https://doi.org/10.1523/JNEUROSCI.0511-10.2010CrossRefPubMedPubMedCentral

27.

Zhang XC, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R (2011) Activation of central TGV neurons by CSD. Ann Neurol 69(5):855–865. https://doi.org/10.1002/ana.22329.ActivationCrossRefPubMedPubMedCentral

28.

Hadjikhani N, Albrecht DS, Mainero C, Ichijo E, Ward N, Granziera C, Zürcher NR, Akeju O, Bonnier G, Price J, Hooker JM, Napadow V, Nahrendorf M, Loggia ML, Moskowitz MA (2020) Extra-axial inflammatory signal in Parameninges in migraine with visual Aura. Ann Neurol 87(6):939–949. https://doi.org/10.1002/ana.25731CrossRefPubMedPubMedCentral

29.

Liktor-Busa E, Blawn KT, Kellohen KL et al (2020) Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake. PLoS One 15(5):e0227463. https://doi.org/10.1371/journal.pone.0227463CrossRefPubMedPubMedCentral

30.

Ghaffari H, Grant SC, Petzold LR, Harrington MG (2020) Regulation of CSF and brain tissue sodium levels by the blood-CSF and blood-brain barriers during migraine. Front Comput Neurosci 14:4. https://doi.org/10.3389/FNCOM.2020.00004CrossRefPubMedPubMedCentral

31.

Ashina M, Terwindt GM, Al-Karagholi MA-M et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397(10283):1496–1504. https://doi.org/10.1016/S0140-6736(20)32162-0CrossRefPubMed

32.

Pellesi L, Al-Karagholi MA-M et al (2021) Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches A Randomized Clinical Trial. JAMA Netw Open 4(8):2118543. https://doi.org/10.1001/jamanetworkopen.2021.18543CrossRef

33.

Hendrikse ER, Bower RL, Hay DL, Walker CS (2019) Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia. 39(3):403–419. https://doi.org/10.1177/0333102418765787CrossRefPubMed

34.

Sundrum T, Walker CS (2017) Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: Implications for migraine. Br J Pharmacol 175(21):4109–4120CrossRef

35.

Edvinsson L, Nilsson E, Jansen-Olesen I (2007) Inhibitory effect of BIBN4096BS, CGRP 8-37, a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150(5):633–640. https://doi.org/10.1038/sj.bjp.0707134CrossRefPubMedPubMedCentral

36.

Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, Tfelt-Hansen P (2008) Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain. 9(3):151–157. https://doi.org/10.1007/s10194-008-0036-8CrossRefPubMedPubMedCentral

37.

Asghar MS, Hansen AE, Kapijimpanga T, van der Geest RJ, van der Koning P, Larsson HBW, Olesen J, Ashina M (2010) Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 75(17):1520–1526. https://doi.org/10.1212/WNL.0b013e3181f9626aCrossRefPubMed

38.

Ghanizada H, Al-Mahdi Al-Karagholi M, Arngrim N et al (2021) Effect of Adrenomedullin on migraine-like attacks in patients with migraine. Neurology. 96(20):e2488–e2499. https://doi.org/10.1212/wnl.0000000000011930CrossRefPubMed

39.

Petersen KA, Birk S, Kitamura K, Olesen J (2009) Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia. 29(1):23–30. https://doi.org/10.1111/j.1468-2982.2008.01695.xCrossRefPubMed

40.

Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB (1995) Permeability of the blood-brain barrier to amylin. Life Sci 57(22):1993–2001. https://doi.org/10.1016/0024-3205(95)02197-QCrossRefPubMed

41.

Dogrukol-Ak D, Banks WA, Tuncel N, Tuncel M (2003) Passage of vasoactive intestinal peptide across the blood-brain barrier. Peptides. 24(3):437–444. https://doi.org/10.1016/S0196-9781(03)00059-7CrossRefPubMed

42.

Ghanizada H, Al-Karagholi MAM, Walker CS et al (2021) Amylin analog Pramlintide induces migraine-like attacks in patients. Ann Neurol 89(6):1157–1171. https://doi.org/10.1002/ana.26072CrossRefPubMed

43.

Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood- brain barrier. J Pharmacol Exp Ther 267(2):690–696PubMed

44.

Ghanizada H, Al-Karagholi MA, Arngrim N, Olesen J, Ashina M (2020) PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia. 40(1):57–67. https://doi.org/10.1177/0333102419864507CrossRefPubMed

45.

Erdling A, Sheykhzade M, Maddahi A, Bari F, Edvinsson L (2013) VIP/PACAP receptors in cerebral arteries of rat: Characterization, localization and relation to intracellular calcium. Neuropeptides 47(2):85–92. https://doi.org/10.1016/j.npep.2012.12.005CrossRefPubMed

46.

Ghanizada H, Al-Karagholi MA, Arngrim N et al (2019) Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: a 3T MRI study. Peptides. 121:170134. https://doi.org/10.1016/j.peptides.2019.170134CrossRefPubMed

47.

Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 132(1):16–25. https://doi.org/10.1093/brain/awn307CrossRefPubMed

48.

Grände G, Labruijere S, Haanes KA, MaassenVanDenBrink A, Edvinsson L (2014) Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. J Headache Pain. 15(1):22. https://doi.org/10.1186/1129-2377-15-22CrossRefPubMedPubMedCentral

49.

Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJH, Andersen MR, Larsson HBW, Fahrenkrug J, Olesen J, Ashina M (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 137(3):779–794. https://doi.org/10.1093/brain/awt369CrossRefPubMed

50.

Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM (2003) Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255(1–2):87–97. https://doi.org/10.1016/S0378-5173(03)00039-5CrossRefPubMed

51.

Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, Olesen J, Ashina M (2006) Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. 26(8):992–1003. https://doi.org/10.1111/j.1468-2982.2006.01149.xCrossRefPubMed

52.

Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 28(3):226–236. https://doi.org/10.1111/j.1468-2982.2007.01497.xCrossRefPubMed

53.

Pellesi L, Al-Karagholi MA, Chaudhry BA et al (2020) Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia 40(11):1223. https://doi.org/10.1177/0333102420937655CrossRef

54.

Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K (1989) Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT. Stroke. 20(12):1733–1736. https://doi.org/10.1161/01.str.20.12.1733CrossRefPubMed

55.

Schulz JM, Al-Khazraji BK, Shoemaker JK (2018) Sodium nitroglycerin induces middle cerebral artery vasodilatation in young, healthy adults. Exp Physiol 103(8):1047–1055. https://doi.org/10.1113/EP087022CrossRefPubMedPubMedCentral

56.

Schoonman GG, Van Der Grond J, Kortmann C, Van Der Geest RJ, Terwindt GM, Ferrari MD (2008) Migraine headache is not associated with cerebral or meningeal vasodilatation - a 3T magnetic resonance angiography study. Brain. 131(8):2192–2200. https://doi.org/10.1093/brain/awn094CrossRefPubMed

57.

Gómez-Vallejo V, Ugarte A, García-Barroso C, Cuadrado-Tejedor M, Szczupak B, Dopeso-Reyes IG, Lanciego JL, García-Osta A, Llop J, Oyarzabal J, Franco R (2016) Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. J Neurochem 136(2):403–415. https://doi.org/10.1111/jnc.13454CrossRefPubMed

58.

Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J (2003) Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia 24(7):547–553CrossRef

59.

Grände G, Nilsson E, Edvinsson L (2013) Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method. Cephalalgia. 33(3):152–159. https://doi.org/10.1177/0333102412468340CrossRefPubMed

60.

Kruuse C, Gupta S, Nilsson E, Kruse L, Edvinsson L (2012) Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. Eur J Pharmacol 674(2–3):345–351. https://doi.org/10.1016/j.ejphar.2011.10.037CrossRefPubMed

61.

Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain. 137(11):2951–2959. https://doi.org/10.1093/brain/awu244CrossRefPubMed

62.

Butt JH, Rostrup E, Hansen AS, Lambertsen KL, Kruuse C (2018) Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura. Brain. 141(10):2943–2951. https://doi.org/10.1093/brain/awy228CrossRefPubMed

63.

Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J (2004) The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24(12):1352–1358. https://doi.org/10.1097/01.WCB.0000143536.22131.D7CrossRefPubMed

64.

Khan S, Amin FM, Christensen CE, Ghanizada H, Younis S, Olinger ACR, de Koning PJH, Larsson HBW, Ashina M (2019) Meningeal contribution to migraine pain: a magnetic resonance angiography study. Brain. 142(1):93–102. https://doi.org/10.1093/brain/awy300CrossRefPubMed

65.

Al-Karagholi MA, Hansen JM, Guo S, Olesen J, Ashina M (2019) Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain. 142(9):2644–2654. https://doi.org/10.1093/brain/awz199CrossRefPubMed

66.

Al-Karagholi MAM, Ghanizada H, Nielsen CAW et al (2020) Cerebrovascular effects of glibenclamide investigated using high-resolution magnetic resonance imaging in healthy volunteers. J Cereb Blood Flow Metab 41(6):1328–1337. https://doi.org/10.1177/0271678X20959294CrossRefPubMedPubMedCentral

67.

Al-Karagholi MA, Ghanizada H, Waldorff Nielsen CA et al (2021) Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain 162(10):2512–2520PubMed

68.

Al-karagholi MA, Ghanizada H, Amalie C et al (2020) Opening of BK Ca channels alters cerebral hemodynamic and causes headache in healthy volunteers. Cephalalgia 40(11):1145–1154. https://doi.org/10.1177/0333102420940681CrossRefPubMed

69.

Kastin AJ, Akerstrom V, Hackler L, Pan W (2001) Adrenomedullin and the blood-brain barrier. Horm Metab Res 33(1):19–25. https://doi.org/10.1055/s-2001-12621CrossRefPubMed

70.

Banks WA, Kastin AJ (1998) Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides. 19(5):883–889. https://doi.org/10.1016/S0196-9781(98)00018-7CrossRefPubMed

71.

Amin FM, Schytz HW (2018) Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. J Headache Pain. 19(1):35. https://doi.org/10.1186/s10194-018-0861-3CrossRefPubMedPubMedCentral

72.

Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140(3):185–191. https://doi.org/10.1016/j.regpep.2006.12.010CrossRefPubMed

73.

Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJH, Larsson HBW, Olesen J, Ashina M (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 32(2):140–149. https://doi.org/10.1177/0333102411431333CrossRefPubMed

74.

Asghar MS, Hansen AE, Larsson HBW, Olesen J, Ashina M (2012) Effect of CGRP and sumatriptan on the BOLD response in visual cortex. J Headache Pain 13(2):159–166. https://doi.org/10.1007/s10194-011-0415-4CrossRefPubMedPubMedCentral

75.

de Vries T, Villalón CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther 211:107528. https://doi.org/10.1016/j.pharmthera.2020.107528CrossRefPubMed

76.

Hostetler ED, Joshi AD, Sanabria-Bohórquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O’Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore CA, Kane SA, Li CC, Hargreaves RJ, de Groot T, Bormans G, van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, de Lepeleire I, Kennedy WP, Blanchard R, Marcantonio EE, Sur C, Cook JJ, van Laere K, Evelhoch JL (2013) In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther 347(2):478–486. https://doi.org/10.1124/jpet.113.206458CrossRefPubMed

77.

Christensen SL, Ernstsen C, Olesen J, Kristensen DM (2020) No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Cephalalgia. 40(9):924–934. https://doi.org/10.1177/0333102420914913CrossRefPubMed

78.

Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F, Strassman AM, Burstein R (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia. 40(3):229–240. https://doi.org/10.1177/0333102419896760CrossRefPubMed

79.

Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501–514. https://doi.org/10.1038/S41582-021-00509-5CrossRefPubMedPubMedCentral

80.

Pearlman EM, Wilbraham D, Dennehy EB et al (2020) Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol 35(5):e2732. https://doi.org/10.1002/HUP.2732CrossRefPubMedPubMedCentral

81.

Clemow DB, Johnson KW, Hochstetler HM et al (2020) Lasmiditan mechanism of action - review of a selective 5-HT 1F agonist. J Headache Pain 21(1):71. https://doi.org/10.1186/S10194-020-01132-3CrossRefPubMedPubMedCentral

82.

Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV (2015) Blood-brain barrier breakdown in the aging human Hippocampus. Neuron. 85(2):296–302. https://doi.org/10.1016/J.NEURON.2014.12.032CrossRefPubMedPubMedCentral

83.

Nation DA, Sweeney MD, Montagne A, Sagare AP, D’Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Chui HC, Law M, Toga AW, Zlokovic BV (2019) Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 25(2):270–276. https://doi.org/10.1038/S41591-018-0297-YCrossRefPubMedPubMedCentral

84.

Afridi SK, Kaube H, Goadsby PJ (2004) Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 110(3):675–680. https://doi.org/10.1016/j.pain.2004.05.007CrossRefPubMed

85.

Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 137(Pt 1):232–241. https://doi.org/10.1093/brain/awt320CrossRefPubMed

86.

Guo S, Vollesen ALH, Olesen J, Ashina M (2016) Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain. 157(12):2773–2781. https://doi.org/10.1097/j.pain.0000000000000702CrossRefPubMed

87.

Al-Karagholi MA-M, Ghanizada H, Nielsen CAW, Hougaard A, Ashina M (2021) Opening of ATP sensitive potassium channels causes migraine attacks with aura. Brain. 2021(8):2322–2332. https://doi.org/10.1093/brain/awab136CrossRef

88.

Oliver KR, Wainwright A, Edvinsson L, Pickard JD, Hill RG (2002) Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 22(5):620–629. https://doi.org/10.1097/00004647-200205000-00014CrossRefPubMed

89.

Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, Messlinger K (2008) Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 507(3):1277–1299. https://doi.org/10.1002/cne.21607CrossRefPubMed

90.

Edvinsson JCA, Warfvinge K, Krause DN, Blixt FW, Sheykhzade M, Edvinsson L, Haanes KA (2019) C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain. 20(1):105. https://doi.org/10.1186/s10194-019-1055-3CrossRefPubMedPubMedCentral

91.

Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson L, Waldvogel HJ, Jamaluddin MA, Russo AF, Hay DL (2015) A second trigeminal CGRP receptor: function and expression of the AMY<inf>1</inf> receptor. Ann Clin Transl Neurol 2(6):595–608. https://doi.org/10.1002/acn3.197CrossRefPubMedPubMedCentral

92.

Tschopp FA, Henke H, Petermann JB, Tobler PH, Janzer R, Hokfelt T, Lundberg JM, Cuello C, Fischer JA (1985) Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci U S A 82(1):248–252. https://doi.org/10.1073/pnas.82.1.248CrossRefPubMedPubMedCentral

93.

Stachniak TJE, Krukoff TL (2003) Receptor activity modifying protein 2 distribution in the rat central nervous system and regulation by changes in blood pressure. J Neuroendocrinol 15(9):840–850. https://doi.org/10.1046/j.1365-2826.2003.01064.xCrossRefPubMed

94.

Hensley K, Pretorius J, Chan B (2018) PAC1 receptor mRNA and protein distribution in rat and human trigeminal and sphenopalatine ganglia, spinal trigeminal nucleus and in dura mater. Cephalalgia 39(7):1–14. https://doi.org/10.1177/0333102418821621CrossRef

95.

Jansen-Olesen I, Baun M, Amrutkar DV, Ramachandran R, Christophersen DV, Olesen J (2014) PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides. 48(2):53–64. https://doi.org/10.1016/j.npep.2014.01.004CrossRefPubMed

96.

Jolivel V, Basille M, Aubert N, de Jouffrey S, Ancian P, le Bigot JF, Noack P, Massonneau M, Fournier A, Vaudry H, Gonzalez BJ, Vaudry D (2009) Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates. Neuroscience. 160(2):434–451. https://doi.org/10.1016/j.neuroscience.2009.02.028CrossRefPubMed

97.

Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, Cha CI (2004) Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol 476(4):388–413. https://doi.org/10.1002/cne.20231CrossRefPubMed

98.

Ploug KB, Sørensen MA, Strøbech L, Klaerke DA, Hay-Schmidt A, Sheykhzade M, Olesen J, Jansen-Olesen I (2008) KATP channels in pig and human intracranial arteries. Eur J Pharmacol 601(1–3):43–49. https://doi.org/10.1016/j.ejphar.2008.10.041CrossRefPubMed

99.

Ploug KB, Boni LJ, Baun M, Hay-Schmidt A, Olesen J, Jansen-Olesen I (2008) K ATP channel expression and pharmacological in vivo and in vitro studies of the K ATP channel blocker PNU-37883A in rat middle meningeal arteries. Br J Pharmacol 154(1):72–81. https://doi.org/10.1038/bjp.2008.86CrossRefPubMedPubMedCentral

100.

Nui K, Saloman JL, Zhang Y, Ro JY (2011) Sex diffferences in the contribution of ATP-sensitive K+ channels in trigeminal ganglia under an acute muscle pain condition. Neuroscience 80:344–352. https://doi.org/10.1038/jid.2014.371CrossRef

101.

Ploug KB, Amrutkar DV, Baun M, Ramachandran R, Iversen A, Lund TM, Gupta S, Hay-Schmidt A, Olesen J, Jansen-Olesen I (2012) K ATP channel openers in the trigeminovascular system. Cephalalgia. 32(1):55–65. https://doi.org/10.1177/0333102411430266CrossRefPubMed

102.

Dunn-Meynell AA, Rawson NE, Levin BE (1998) Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res 814(1–2):41–54. https://doi.org/10.1016/S0006-8993(98)00956-1CrossRefPubMed

103.

Sausbier U, Sausbier M, Sailer CA, Arntz C, Knaus HG, Neuhuber W, Ruth P (2006) Ca2+−activated K+ channels of the BK-type in the mouse brain. Histochem Cell Biol 125(6):725–741. https://doi.org/10.1007/s00418-005-0124-7CrossRefPubMed

104.

Wulf-Johansson H, Amrutkar DV, Hay-Schmidt A, Poulsen AN, Klaerke DA, Olesen J, Jansen-Olesen I (2010) Localization of large conductance calcium-activated potassium channels and their effect on calcitonin gene-related peptide release in the rat trigemino-neuronal pathway. Neuroscience. 167(4):1091–1102. https://doi.org/10.1016/j.neuroscience.2010.02.063CrossRefPubMed

105.

Poulsen AN, Wulf H, Hay-Schmidt A, Jansen-Olesen I, Olesen J, Klaerke DA (2009) Differential expression of BK channel isoforms and β-subunits in rat neuro-vascular tissues. Biochim Biophys Acta Biomembr 1788(2):380–389. https://doi.org/10.1016/j.bbamem.2008.10.001CrossRef

Title: Brain barriers and their potential role in migraine pathophysiology
Authors: Astrid Wiggers
Håkan Ashina
Nouchine Hadjikhani
Abhay Sagare
Berislav V. Zlokovic
Martin Lauritzen
Messoud Ashina
Publication date: 01-12-2022
Publisher: Springer Milan
Keywords: Migraine
Aura
Headache
Published in: The Journal of Headache and Pain / Issue 1/2022
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-021-01365-w

At a glance: The STEP trials

Springer Medicine

Brain barriers and their potential role in migraine pathophysiology

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients

Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review

Serum CGRP in migraine patients using erenumab as preventive treatment

Persistent headache after first-ever ischemic stroke: clinical characteristics and factors associated with its development

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress